Market News

$-0.31 EPS Expected for OncoMed Pharmaceuticals, Inc. (OMED); 7digital Group plc (LON:7DIG) Had 3 Analysts Last Week

Among 4 analysts covering 7digital Group Plc (LON:7DIG), 3 have Buy rating, 1 Sell and 0 Hold. Therefore 75% are positive. 7digital Group Plc had 36 analyst reports since September 7, 2015 according to SRatingsIntel. The stock has “Buy” rating by Investec on Wednesday, January 6. The firm earned “Corporate” rating on Wednesday, March 30 by FinnCap. The rating was maintained by FinnCap on Thursday, November 9 with “Corporate”. The firm has “Corporate” rating given on Thursday, January 21 by FinnCap. The rating was maintained by FinnCap on Monday, September 28 with “Corporate”. The rating was maintained by FinnCap with “Corporate” on Tuesday, January 17. The stock of 7digital Group plc (LON:7DIG) has “Corporate” rating given on Thursday, April 13 by FinnCap. The stock has “Not Rated” rating by Shore Capital on Tuesday, June 20. The rating was maintained by FinnCap with “Corporate” on Monday, September 19. Investec maintained it with “Buy” rating and GBX 30 target in Wednesday, January 13 report. See 7digital Group plc (LON:7DIG) latest ratings:

09/11/2017 Broker: FinnCap Rating: Corporate Old Target: GBX 14.00 New Target: GBX 14.00 Maintain
26/09/2017 Broker: FinnCap Rating: Corporate Old Target: GBX 14.00 New Target: GBX 14.00 Maintain

Analysts expect OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) to report $-0.31 EPS on March, 14.They anticipate $0.39 EPS change or 55.71% from last quarter’s $-0.7 EPS. After having $-0.28 EPS previously, OncoMed Pharmaceuticals, Inc.’s analysts see 10.71% EPS growth. The stock decreased 0.51% or $0.01 during the last trading session, reaching $1.94. About 307,864 shares traded or 29.71% up from the average. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has declined 70.06% since February 10, 2017 and is downtrending. It has underperformed by 86.76% the S&P500.

7digital Group plc operates as a B2B digital music and radio services firm in the United Kingdom, rest of Europe, and internationally. The company has market cap of 19.05 million GBP. The firm operates through three divisions: Content, Licensing, and Creative. It currently has negative earnings. The Company’s Content division is involved in the sale of digital music.

The stock decreased 1.54% or GBX 0.07 during the last trading session, reaching GBX 4.8. About 2.17 million shares traded or 399.95% up from the average. 7digital Group plc (LON:7DIG) has 0.00% since February 10, 2017 and is . It has underperformed by 16.70% the S&P500.

Investors sentiment increased to 0.71 in 2017 Q3. Its up 0.12, from 0.59 in 2017Q2. It increased, as 12 investors sold OncoMed Pharmaceuticals, Inc. shares while 19 reduced holdings. 7 funds opened positions while 15 raised stakes. 13.02 million shares or 24.21% less from 17.17 million shares in 2017Q2 were reported. Glenmede Company Na owns 3,600 shares or 0% of their US portfolio. Moreover, Bridgeway has 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Barclays Pcl owns 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 1,868 shares. Bank & Trust Of Montreal Can, Ontario – Canada-based fund reported 8,000 shares. Vanguard reported 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Manufacturers Life Insurance Company The reported 2,762 shares. France-based Axa has invested 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Commercial Bank Of Ny Mellon Corporation has 23,538 shares for 0% of their portfolio. The Maryland-based Proshare Advsr Limited has invested 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Deutsche National Bank Ag holds 1,416 shares. 36,055 were reported by Morgan Stanley. First Eagle Mgmt Lc has invested 0% of its portfolio in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Cannell Peter B And Inc has 0.05% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 303,971 shares. Citadel Advisors Ltd Liability Company reported 33,587 shares. Iguana Healthcare Mngmt Lc has 350,000 shares for 0.88% of their portfolio.

Since October 10, 2017, it had 0 insider purchases, and 5 sales for $27,111 activity. $5,295 worth of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) shares were sold by Gurney Austin. Hager Alicia J. also sold $5,295 worth of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) on Tuesday, October 10. On Tuesday, October 10 Lewicki John A. sold $5,295 worth of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) or 1,248 shares. Another trade for 1,248 shares valued at $5,295 was made by Patel Sunil on Tuesday, October 10. Shares for $5,931 were sold by HASTINGS PAUL J on Tuesday, October 10.

OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell and immuno-oncology therapeutics. The company has market cap of $73.44 million. The company's product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It currently has negative earnings. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand.

Among 10 analysts covering OncoMed Pharmaceuticals (NASDAQ:OMED), 5 have Buy rating, 0 Sell and 5 Hold. Therefore 50% are positive. OncoMed Pharmaceuticals had 18 analyst reports since September 9, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Friday, December 4 by Wells Fargo. SunTrust initiated OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) on Tuesday, December 20 with “Buy” rating. The stock of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) earned “Buy” rating by H.C. Wainwright on Thursday, September 22. The firm has “Buy” rating by Jefferies given on Wednesday, August 10. On Wednesday, September 9 the stock rating was initiated by Jefferies with “Buy”. The stock has “Outperform” rating by BMO Capital Markets on Tuesday, April 12. Mizuho maintained OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) rating on Tuesday, January 26. Mizuho has “Buy” rating and $15 target. The company was maintained on Thursday, August 24 by Jefferies. The rating was downgraded by BMO Capital Markets to “Market Perform” on Tuesday, April 11. The company was maintained on Wednesday, March 9 by JMP Securities.

Leave a Reply

Your email address will not be published. Required fields are marked *